ARCH Venture Fund XIII, L.P.

SEC Form 4 insider trading activity

ARCH Venture Fund XIII, L.P. has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Mar 9, 2026.

On the most recent filing, ARCH Venture Fund XIII, L.P. is listed as 10% Owner at Lyell Immunopharma, Inc. Inside the rolling window, ARCH Venture Fund XIII, L.P. reported 1 open-market purchase totaling $12.5M in LYEL and no open-market sales.

Companies traded

Other insiders at LYEL

Insider Buying

$12.5M

reported purchases (SEC code P)

Insider Selling

$0

reported sales (SEC code S)

Companies

1

in the rolling window

Source
LYEL
ARCH Venture Fund XIII, L.P.
Purchase$12.5MMar 9SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has ARCH Venture Fund XIII, L.P. made?

ARCH Venture Fund XIII, L.P. has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company since 2026.

Which companies does ARCH Venture Fund XIII, L.P. trade?

ARCH Venture Fund XIII, L.P. has filed SEC Form 4 disclosures for 1 company, including LYEL.

When was ARCH Venture Fund XIII, L.P.'s most recent SEC Form 4 filing?

ARCH Venture Fund XIII, L.P.'s most recent SEC Form 4 filing on Tracefour is dated Mar 9, 2026.

What is ARCH Venture Fund XIII, L.P.'s total buy and sell value in the current window?

Inside the rolling retention window, ARCH Venture Fund XIII, L.P. bought $12.5M and sold $0 based on SEC Form 4 filings.

What was ARCH Venture Fund XIII, L.P.'s largest disclosed transaction?

The largest disclosed transaction in the current window is a purchase of 488,090 LYEL shares on 2026-03-06, worth $12.5M, per SEC Form 4 filings.